Simcere Pharmaceutical Group’s monoclonal antibody rademikibart (CBP-201) met the primary endpoint in a Chinese Phase 3 study in adults and adolescents with moderate to severe atopic dermatitis. The company reported primary endpoint achievement supporting continued progress in a competitive market that includes multiple biologic and pipeline-stage candidates. Rademikibart targets immune pathways central to atopic dermatitis, and the reported Phase 3 result is expected to support regulatory submissions in China. Investors will watch safety, durability of response, and comparative positioning versus existing standards of care. The readout further signals that China-developed biologics continue to scale into late-stage programs despite global pricing and access pressures.